Healthy Volunteer Clinical Trial
Official title:
Use of Pap Smear Derived Cells to Analyze the Expression of SLC6A14 and GPR81 Genes
SLC6A14 may serve as a biomarker for cervical dysplasia or cervical cancer.
SLC6A14 amino acid transporter Previous research has shown that the expression of the amino
acid transporter SLC6A14 is up-regulated in cervical cancer1. Studies on breast, colon and
pancreatic cancer cells have shown that SLC6A14 amino acid transporter serves the role of
supporting amino acid nutrition to these cancer cells2,3,4. It has also been shown that
genetic deletion or pharmacologic blockade of the above transporter will suppress the growth
of the tumor cells both in vitro and in vivo4,5,6.
We are interested in exploring the expression of SLC6A14 transporter in normal cervical
epithelial cells, in cervical dysplasia and cervical cancer; and to see if expression of this
transporter has any correlation to presence/severity of cervical dysplasia/cancer, and also
to see if this may serve as a biomarker to predict or diagnose the presence of cervical
dysplasia and cervical cancer.
GPR81, a G-protein coupled receptor for lactate Human vagina is predominantly colonized by
Lactobacilli, which convert glycogen in the vaginal epithelial cells to lactic acid. Some
species of Lactobacilli also produce hydrogen peroxide. Both lactate and H2O2 help to keep
the vaginal pH low (acidic <4.5) and also help in preventing colonization of the vagina by
pathogenic bacteria. When the levels of Lactobacilli in the vaginal micro environment change
(as with certain vaginal infections, decline in estrogen levels etc), levels of lactate
decline and H2O2 decline—thus predisposing women to vaginal infections.
Vaginal and cervical fluids contain lactate in millimolar concentrations. Recent studies have
identified a G-protein-coupled cell-surface receptor for lactate,-called GPR81. Studies from
Dr. Ganapathy's lab have shown that activation of the receptor GPR81 in B lymphocytes
enhances the production of IgA antibody, which plays a role in defense mechanisms of mucosal
surfaces. IgA antibodies are seen in high levels in the intestinal, colonic, lung mucosa as
well as vaginal epithelial surfaces. These IgA antibodies protect the colonization of mucosal
surfaces by pathogenic bacteria. Thus GPR 81 is an anti-inflammatory molecule. Hence it may
inversely correlate with cervical dysplasia. We propose to investigate if the vaginal and
cervical epithelial cells express this GPR81, whether GPR81 expression correlates to cervical
dysplasia.
If a correlation exists between lactate levels and GPR81 expression, declining Lactobacilli
levels with associated decline in lactate levels, could lead to decreased GPR81 expression on
epithelial cells, and thus decline in IgA antibody secretion. This could be the reason for
vaginal infections with decreased Lactobacilli. If infection with HPV virus occurs, this will
lead to abnormalities in the Pap smear and potential cervical dysplasia in the future.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01579149 -
A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent
|
Phase 1 |